In the article by Panzer-Grümayer et al entitled “Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia,” which appeared in the February 1, 2000, issue of Blood (Volume 95: 790–794), a correction should be noted regarding the treatment protocol: All children stratified into SRG and MRG received induction treatment (protocol 1), consolidation treatment (protocol M), and reinduction treatment (protocol 2), followed by maintenance treatment. Protocol 2 was omitted in the original article. It consisted of phase 1 with daily dexamethasone for 3 weeks, weekly vincristine and doxorubicin ×4 starting at week 2, and 1-asparaginase ×4 during weeks 2 and 3, followed by phase 2 with cyclophosphamide on day 36, ARA-C 4×/wk plus intrathecal methotrexate on days 38 and 45.
ERRATUM|
May 15, 2000
Erratum in Panzer-Grümayer et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
Blood (2000) 95 (10): 3010.
Connected Content
Citation
Erratum in Panzer-Grümayer et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.. Blood 2000; 95 (10): 3010. doi: https://doi.org/10.1182/blood.V95.10.3010
Download citation file: